Paion AG banner

Paion AG
F:PA8

Watchlist Manager
Paion AG Logo
Paion AG
F:PA8
Watchlist
Price: 0.16 EUR 14.7% Market Closed
Market Cap: €167.8k

Net Margin

-1.7%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1.7%
=
Net Income
€-579k
/
Revenue
€33.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1.7%
=
Net Income
€-579k
/
Revenue
€33.2m

Peer Comparison

Country Company Market Cap Net
Margin
DE
Paion AG
XETRA:PA8
1.8m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
204.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
190B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Germany
Percentile
31th
Based on 3 835 companies
31th percentile
-1.7%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

Paion AG
Glance View

Market Cap
167.8k EUR
Industry
Biotechnology

PAION AG operates as a pharmaceutical company. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 56 full-time employees. The company went IPO on 2012-03-29. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

PA8 Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1.7%
=
Net Income
€-579k
/
Revenue
€33.2m
How has Net Margin changed over time?

Over the last 2 years, Paion AG’s Net Margin has decreased from 11.3% to -1.7%. During this period, it reached a low of -305.6% on Dec 31, 2021 and a high of 11.3% on Dec 1, 2020.

Back to Top